| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FNTB; Protein farnesyltransferase subunit beta; FTase-beta; CAAX farnesyltransferase subunit beta; Ras proteins prenyltransferase subunit beta |
| Entrez GeneID | 100529261 |
| WB Predicted band size | Calculated MW: 49 kDa; Observed MW: 49 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human FNTB |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于FNTB抗体的3篇文献示例及其摘要概括：
1. **文献名称**：*"Farnesyltransferase β-subunit (FNTB) as a Novel Biomarker in Colorectal Cancer: Expression Analysis and Prognostic Implications"*
**作者**：Smith J, et al.
**摘要**：本研究通过免疫组化分析发现，FNTB在结直肠癌组织中高表达，且与患者预后不良显著相关。研究提示FNTB可能作为潜在的治疗靶点或预后标志物。
2. **文献名称**：*"Development and Validation of a Monoclonal Antibody Specific to Human FNTB for Functional Studies in Ras Signaling"*
**作者**：Chen L, et al.
**摘要**：文章报道了一种高特异性抗FNTB单克隆抗体的开发，并通过敲除实验验证其在Western blot和免疫荧光中的应用。该抗体成功用于揭示FNTB在Ras蛋白膜定位中的关键作用。
3. **文献名称**：*"Targeting FNTB in Cancer Therapy: Insights from Small Molecule Inhibitors and Antibody-Based Approaches"*
**作者**：Rodriguez M, et al.
**摘要**：综述讨论了FNTB在癌症中的功能及其抑制剂开发进展，强调抗体技术在检测FNTB表达水平和评估抑制剂疗效中的应用，为联合治疗策略提供理论依据。
(注：以上文献为示例性内容，实际文献需通过学术数据库检索获取。)
The farnesyltransferase beta (FNTB) antibody targets the β-subunit of farnesyltransferase, a heterodimeric enzyme critical for post-translational protein modification. FNTB, along with the α-subunit (FNTA), catalyzes the attachment of farnesyl groups to cysteine residues in specific target proteins, notably Ras family GTPases. This farnesylation is essential for membrane localization and activation of these proteins, which regulate cell signaling, proliferation, and survival. Dysregulation of FNTB-mediated farnesylation is implicated in cancer, neurodegenerative disorders, and premature aging syndromes like Hutchinson-Gilford progeria.
FNTB antibodies are vital tools for studying protein prenylation mechanisms and disease pathways. They enable detection of FNTB expression levels via Western blot, immunohistochemistry, or immunofluorescence, aiding research on its role in oncogenesis—particularly in cancers driven by Ras mutations (e.g., pancreatic, colorectal). Additionally, these antibodies support drug development efforts, as farnesyltransferase inhibitors (FTIs) have been explored for cancer and progeria treatment. By elucidating FNTB interactions with substrates or inhibitors, researchers can refine therapeutic strategies. Validation of FNTB antibodies includes specificity checks using knockout controls and functional assays to confirm their utility in both basic and translational research contexts.
×
